全文获取类型
收费全文 | 94篇 |
免费 | 6篇 |
专业分类
儿科学 | 11篇 |
妇产科学 | 1篇 |
基础医学 | 11篇 |
临床医学 | 16篇 |
内科学 | 17篇 |
皮肤病学 | 2篇 |
神经病学 | 11篇 |
外科学 | 8篇 |
综合类 | 1篇 |
预防医学 | 1篇 |
药学 | 11篇 |
肿瘤学 | 10篇 |
出版年
2021年 | 2篇 |
2015年 | 6篇 |
2014年 | 5篇 |
2013年 | 2篇 |
2012年 | 2篇 |
2011年 | 1篇 |
2010年 | 2篇 |
2009年 | 5篇 |
2008年 | 1篇 |
2007年 | 3篇 |
2006年 | 3篇 |
2005年 | 1篇 |
2004年 | 2篇 |
2003年 | 2篇 |
1998年 | 2篇 |
1997年 | 8篇 |
1996年 | 8篇 |
1995年 | 4篇 |
1994年 | 8篇 |
1993年 | 3篇 |
1992年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1984年 | 3篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
1957年 | 2篇 |
1956年 | 2篇 |
1955年 | 9篇 |
1954年 | 5篇 |
排序方式: 共有100条查询结果,搜索用时 265 毫秒
1.
Coexistence of renal replacement lipomatosis with xanthogranulomatous pyelonephritis 总被引:1,自引:0,他引:1
YUKO SAKATA NOBUTAKA KINOSHITA HIROMI KATO YASUSHI YAMADA YOSHIKI SUGIMURA 《International journal of urology》2004,11(1):44-46
We report on a case of coexistence of replacement lipomatosis with xanthogranulomatous pyelonephritis (XGP) in the same kidney associated with staghorn calculi. A 63-year-old man was admitted to hospital complaining of a right abdominal mass. Computed tomography (CT) showed renal parenchymal atrophy with extremely increased perirenal fat. Right nephrectomy was performed. Postoperative diagnosis was renal replacement lipomatosis with XGP. Renal replacement lipomatosis and XGP have several similarities in terms of clinical background and CT findings. Sometimes it is difficult to differentiate them from malignant diseases. It is extremely rare that both conditions coexist in the same kidney. To our knowledge, only one such case has been reported. 相似文献
2.
3.
HISAKI MAKIMOTO M.D. Ph.D. IKUTARO NAKAJIMA M.D. KOJI MIYAMOTO M.D. YUKO YAMADA M.D. HIDEO OKAMURA M.D. TAKASHI NODA M.D. Ph.D. TAKESHI AIBA M.D. Ph.D. SHIRO KAMAKURA M.D. Ph.D. KENGO KUSANO M.D. Ph.D. WATARU SHIMIZU M.D. Ph.D. KAZUHIRO SATOMI M.D. Ph.D. 《Pacing and clinical electrophysiology : PACE》2015,38(5):630-640
4.
YUKO UCHIMURA‐MAKITA M.D. YUKIKO NAKANO M.D. Ph.D. TAKEHITO TOKUYAMA M.D. MAI FUJIWARA M.D. YOSHIKAZU WATANABE M.D. AKINORI SAIRAKU M.D. HIROSHI KAWAZOE M.D. HIROYA MATSUMURA M.D. NOZOMU ODA M.D. HIROKI IKANAGA M.D. CHIKAAKI MOTODA M.D. KENTA KAJIHARA M.D. Ph.D. NOBORU ODA M.D. Ph.D. RICHARD L. VERRIER Ph.D. YASUKI KIHARA M.D. Ph.D. 《Journal of cardiovascular electrophysiology》2014,25(9):1021-1027
5.
SHU TAKABATAKE M.D. KENSHI HAYASHI M.D. CHIAKI NAKANISHI M.D. HIROYUKI HAO M.D. KENJI SAKATA M.D. MASA‐AKI KAWASHIRI M.D. TAKEHISA MATSUDA Ph.D. MASAKAZU YAMAGISHI M.D. 《Journal of interventional cardiology》2014,27(1):63-72
Objectives
We evaluated the in vivo performance of a newly devised vascular endothelial growth factor (VEGF)‐bound stent in a porcine coronary model.Background
An anti‐CD34 antibody‐bound stent, which captures endothelial progenitor cells (EPCs) to accelerate tissue formation, did not reduce intimal hyperplasia. By targeting the VEGF receptor, which is expressed on endothelial‐lineage cells, we developed VEGF‐bound stents that may enable selective capture of EPCs followed by rapid endothelialization.Methods
Metallic stents were first coated with poly‐(ethylene‐co‐vinyl alcohol), and then chemically bound with either VEGF or anti‐CD34 antibody. These stents were placed in porcine coronary arteries for up to 14 days. Stent surface was evaluated by immunohistochemistry and by scanning electron microscope (SEM).Results
After 2‐day stenting with VEGF‐bound stents, small populations of KDR (VEGF receptor‐2)‐positive cells adhered to the stent struts. After 7‐ and 14‐day stenting, struts were fully covered with newly regenerated tissue. SEM images showed that the uniform tissue formed on struts was morphologically similar to native endothelium and was continuously connected with adjacent native endothelium. On the other hand, for the anti‐CD34 antibody‐bound stents, stent struts were rapidly covered by newly generated tissue that consisted of multicellular aggregates.Conclusions
Compared with anti‐CD34 antibody‐bound stents, VEGF‐bound stents provide highly selective capture of EPCs, followed by rapid formation of intact endothelium tissue at an early period of stenting. These results suggest that VEGF‐bound stents could represent a promising therapeutic option for cardiovascular stenting, although further long‐term follow‐up experiment with double‐blinded fashion is needed prior to clinical application. (J Interven Cardiol 2014;27:63–72)6.
7.
HARUAKI YAJIMA NOBUTAKA FUJII YORIKO HIROTA YUKO NASADA YUKO HIRAI TERUMI NAKAJIMA 《Chemical biology & drug design》1980,16(5):426-432
The tetradecapeptide amide corresponding to the entire amino acid sequence of a wasp venom (polistes mastoparan), isolated from Polistes jadwagae, was synthesized using the trifluoroacetic acid-thioanisole deprotecting procedure. 相似文献
8.
NAOTO TOMINAGA ANNIE ROBERT YUKO IZUHARA SHUICHI OHTOMO TAKASHI DAN KAZUO CHIHARA KIYOSHI KUROKAWA CHARLES VAN YPERSELE DE STRIHOU TOSHIO MIYATA 《Nephrology (Carlton, Vic.)》2009,14(6):581-587
Aim: Angiotensin II type 1 receptor blockers (ARB) retard the progression of hypertensive diabetic kidney disease. Clinical evidence suggests that the dose of ARB required to correct hypertension is suboptimal for renoprotection evaluated by proteinuria. No systematic, prospective study has yet evaluated separately the effect of increasing doses of ARB on blood pressure and proteinuria.
Methods: Over a period of 8 weeks, the effect of seven constant doses of an ARB, valsartan (4–160 mg/kg per day), on blood pressure and proteinuria taken as a surrogate marker of nephropathy in a hypertensive, type 2 diabetic rat model, the spontaneously hypertensive/NIH-corpulent rat (SHR/NDmcr-cp), was assessed. In this spontaneously hypertensive rat strain, a genetic mutation in the leptin receptor gene is associated with hyperphagia leading to obesity with metabolic syndrome and eventually to nephropathy.
Results: No additional blood pressure lowering was observed above 120 mg/kg per day of valsartan, suggesting that a dose of 80–120 mg/kg per day had a maximal effect. Nevertheless, higher doses of valsartan further reduced proteinuria in a dose-dependent fashion suggesting the absence of a maximal dose. Obesity, hyperglycaemia and hypercholesterolaemia were unaffected but hypertriglyceridaemia was partially corrected at various ARB doses.
Conclusion: ARB improve renoprotection at doses above those required for a maximal effect on blood pressure. The mechanism of the renoprotection obtained at high doses of ARB is yet to be elucidated. 相似文献
Methods: Over a period of 8 weeks, the effect of seven constant doses of an ARB, valsartan (4–160 mg/kg per day), on blood pressure and proteinuria taken as a surrogate marker of nephropathy in a hypertensive, type 2 diabetic rat model, the spontaneously hypertensive/NIH-corpulent rat (SHR/NDmcr-cp), was assessed. In this spontaneously hypertensive rat strain, a genetic mutation in the leptin receptor gene is associated with hyperphagia leading to obesity with metabolic syndrome and eventually to nephropathy.
Results: No additional blood pressure lowering was observed above 120 mg/kg per day of valsartan, suggesting that a dose of 80–120 mg/kg per day had a maximal effect. Nevertheless, higher doses of valsartan further reduced proteinuria in a dose-dependent fashion suggesting the absence of a maximal dose. Obesity, hyperglycaemia and hypercholesterolaemia were unaffected but hypertriglyceridaemia was partially corrected at various ARB doses.
Conclusion: ARB improve renoprotection at doses above those required for a maximal effect on blood pressure. The mechanism of the renoprotection obtained at high doses of ARB is yet to be elucidated. 相似文献
9.
T. OHMORI† Y. YATOMI‡ T. NONAKA† Y. KOBAYASHI† S. MADOIWA J. MIMURO Y. OZAKI§ Y. SAKATA 《Journal of thrombosis and haemostasis》2006,4(6):1271-1278
OBJECTIVES: Although the concept of aspirin resistance is extensively reported in medical literature, its precise mechanisms and clinical outcomes are largely unknown. In this study, we examined individual thromboxane biosynthesis and platelet aggregation in aspirin-treated patients, and whether the results of a platelet aggregation test influenced clinical outcomes. RESULTS: Subjects taking 81 mg of aspirin (n = 50) and controls (n = 38) were evaluated for platelet aggregation and platelet cyclooxygenase-1 (COX-1) activity by measuring collagen-induced thromboxane B2 production. For aggregometry, both light transmission (LT) and laser-light scattering methods were employed to quantitatively evaluate aggregate sizes and numbers. Aspirin treatment resulted in the inhibition of collagen-induced platelet aggregation, particularly the transition from small to large platelet aggregates. Although platelet COX-1 activity seemed to be uniformly inhibited in all patients, platelet aggregation studies showed great inter-individual differences; variation in platelet COX-1 activity only accounted for 6-20% of the individual aggregations. Factor analysis revealed the existence of a common factor (other than platelet COX-1) that explained 48.4% of the variations in platelet aggregation induced by collagen, adenosine diphosphate (ADP), and collagen-related peptide. We then prospectively enrolled 136 aspirin-treated patients in our study, and we found that being in the upper quartile level of LT, or with large aggregate formation induced by collagen, was an independent risk factor for developing cardiovascular events within 12 months [hazard ratio (HR) = 7.98, P = 0.008 for LT; HR = 7.76, P = 0.007 for large aggregates]. On the other hand, the existence of diabetes mellitus was an independent risk factor for overall outcomes (HR 1.30-11.9, P = 0.015-0.033). CONCLUSIONS: Aspirin resistance expressed as unsuppressed platelet COX-1 activity is a rare condition in an out-patient population. Other factor(s) affecting collagen-induced platelet aggregation may influence early outcomes in aspirin-treated patients. 相似文献
10.
OSAMU KINOSHITA MINORU HONGO YUKO SAIKAWA TSUTOMU KATSUYAMA MASAO TANAKA MASASHI TAKEDA HIROAKI YAMAMOTO MITSUAKI ISOBE MORIE SEKIGUCHI 《Pacing and clinical electrophysiology : PACE》1997,20(12):2949-2953
The purpose of this study was to evaluate heart rate variability (HRV) in patients with familial amyloid polyneuropathy (FAP) using the time- and frequency-domain analysis. The study population consisted of 19 patients with FAP, and 19 age and sex matched normal volunteers. The 24-hour Holter recordings of all subjects in sinus rhythm and off medication were analyzed. Five time-domain indices of HRV were computed. The frequency component of HRV was calculated by fast Fourier transform analysis of the RR intervals. The power spectrum of the low frequency (LF) between 0.04–0.15 Hz and high frequency (HF) between 0.15–0.40 Hz and the LF/HF ratio was calculated. Global measures of HRV including the standard deviation of the mean of RR intervals (SDNN) and the standard deviation of 5-minute mean RR intervals (SDANN) were decreased in patients with FAP. Specific vagal influences on HRV including the proportion of RR intervals more than 50 milliseconds different (pNN50) and the HF power on spectral analysis were less in patients with FAP. LF power and LF/HF ratio were more decreased in patients with FAP at the advanced stage than at the early stage. In conclusion, HRV was significantly decreased in patients with FAP at the early stage, and sympathetic activity was more decreased in patients at the advanced stage. These findings suggest that the decrease of the HRV is an indicator of this disease and the power spectral analysis of the HRV is beneficial in assessing the severity of the autonomic dysfunction. 相似文献